279 related articles for article (PubMed ID: 3513943)
41. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report.
Piver MS; Malfetano J; Baker TR; Lele SB; Marchetti DL
Gynecol Oncol; 1989 Oct; 35(1):69-72. PubMed ID: 2792905
[TBL] [Abstract][Full Text] [Related]
43. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide.
Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ
Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331
[TBL] [Abstract][Full Text] [Related]
44. [Effectiveness of 3-drug therapy in patients with advanced ovarian cancer].
Kwaśniewska-Rokicińska C; Kaleta B; Kumor-Głodny T
Ginekol Pol; 1989 Feb; 60(2):86-9. PubMed ID: 2680790
[TBL] [Abstract][Full Text] [Related]
45. Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin.
Belinson JL; McClure M; Ashikaga T; Krakoff IH
Cancer; 1984 Nov; 54(9):1983-90. PubMed ID: 6548172
[TBL] [Abstract][Full Text] [Related]
46. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg.
De Pree N; Wils J
Anticancer Res; 1989; 9(6):1873-5. PubMed ID: 2697191
[TBL] [Abstract][Full Text] [Related]
48. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin.
Stratton JA; Kucera PR; Rettenmaier MA; Dobashi K; Micha JP; Braly PS; Berman ML; DiSaia PJ
Gynecol Oncol; 1986 Nov; 25(3):302-10. PubMed ID: 3781341
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
[TBL] [Abstract][Full Text] [Related]
50. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
51. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
[TBL] [Abstract][Full Text] [Related]
52. [Chemotherapy of advanced ovarian cancer. Göttingen-Hannover studies].
Kühnle H; Hilfrich J
Onkologie; 1985 Dec; 8(6):374-82. PubMed ID: 3912694
[TBL] [Abstract][Full Text] [Related]
53. Intraperitoneal cisplatin with intravenous cyclophosphamide and doxorubicin for previously untreated stage III and IV ovarian carcinoma.
Young JA; Garretson F; Westlake DL; Illig WP; Vogl SE
Cancer Invest; 1989; 7(6):565-70. PubMed ID: 2630007
[TBL] [Abstract][Full Text] [Related]
54. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
Fanning J; Bennett TZ; Hilgers RD
Obstet Gynecol; 1992 Dec; 80(6):954-60. PubMed ID: 1333066
[TBL] [Abstract][Full Text] [Related]
55. Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide.
Bezwoda WR
Med Pediatr Oncol; 1986; 14(1):26-9. PubMed ID: 3512971
[TBL] [Abstract][Full Text] [Related]
56. Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma.
De Lena M; Lorusso V; Romito S
Cancer Treat Rep; 1986 Jul; 70(7):893-5. PubMed ID: 3719581
[TBL] [Abstract][Full Text] [Related]
57. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
Gadducci A; Brunetti I; Bruzzone M; Carnino F; Chiara S; Conte PF; Fioretti P; Foglia G; Ragni N
Eur J Gynaecol Oncol; 1992; 13(1 Suppl):36-9. PubMed ID: 1511712
[TBL] [Abstract][Full Text] [Related]
58. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
Levenback C; Burke TW; Silva E; Morris M; Gershenson DM; Kavanagh JJ; Wharton JT
Gynecol Oncol; 1992 Sep; 46(3):317-21. PubMed ID: 1526508
[TBL] [Abstract][Full Text] [Related]
59. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial.
Tomirotti M; Perrone S; Giè P; Canaletti R; Carpi A; Biasoli R; Lombardi F; Giovanninetti A; Mensi F; Villa S
Tumori; 1988 Oct; 74(5):573-7. PubMed ID: 3217992
[TBL] [Abstract][Full Text] [Related]
60. Combined cyclophosphamide, adriamycin and cis-platinum in advanced ovarian cancer resistant to chlorambucil and cis-platinum.
Mann GJ; Malden LT; Solomon HJ; Tattersall MH
Gynecol Oncol; 1985 Jun; 21(2):215-9. PubMed ID: 3886497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
